Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced today that many retina specialists throughout the U.S. are now using ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg to treat patients with diabetic macular edema (DME). The first injections of ILUVIEN in the U.S. were captured during a live web event attended by more than 250 eye care professionals. ILUVIEN is the first multiyear eye implant designed to deliver a continuous, submicrogram daily dose of steroid to the retina for 36 months with one injection. ILUVIEN is indicated for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP).
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7496251-iluvien-dme/
A recent survey conducted by DSM Nutritional Products found that 83 percent of adults in the U.S. believe worsening eye health is inevitable with age. What many people don’t realize is that there’s a connection between healthy eyes and proper nutrition, and it goes beyond eating carrots.
According to Dr. Kimberly Reed, optometrist and Ocular Nutrition Society board member, “Incorporating certain nutrients into the diet can support a lifetime of healthy vision and help protect against serious conditions, including cataracts and age-related macular degeneration (AMD). The latter affects more than 2 million Americans and can lead to severe visual impairment.”
To view Multmedia News Release, go to: http://www.multivu.com/players/English/7129751-dsm-nutritional-products-eye-health-survey/
Medical researchers are making unprecedented progress into understanding why women suffer disproportionately from a number of diseases. Those insights are providing information to help develop medicines to attack diseases such as osteoporosis, multiple sclerosis, depression, rheumatoid arthritis and age-related macular degeneration, all of which affect more women than men.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/phrma/50270/
